CNS degeneration, damage and recovery  - Stratification and Cell Therapy 

In the neurological therapeutic areas, CytoSage is positioning to address the unmet medical need of neurological degeneration (FTD, ALS and AD), traumatic brain injury (TBI) and stroke. Cytosage is engaged in utlizing advanced neurological and immune/inflammatory biomarker technology for therapeutic development. Key to that biomarker monitoring activity is the stratification of patients with respect to lesional subtype and prognosis, assisting decision making in therapy application.   

Allogeneic Regulatory T cells (Tregs)

Cytosage has decades of clinical cell therapy development experience that extends from preclinical to conduct of phase 1 in trauma and phase 2 and 3 clinical trials in stroke and secondary consequences of trauma, eg ARDS and immunological disease with associated neuronal co-morbidity, such as frontal temporal dimentia (FTD) and stroke in systemic lupus erythematosus (SLE). Cytosage have access to both a continued source of human Tregs for generation of an allogeneic immunomodulatory/anti-inflammatory cell therapy and cGMP facilities for advancement of cell therapy through clinical stages. 

Immunomodulation and anti-inflammatory monitoring

Through their prior experience in anti-inflammatory cell therapy development and human immune cell pharmacology, Cytosage’s cell therapy development already incorporates the necessary anti-inflammatory potency monitoring across multiple immune cell types for regulatory purposes.